Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression

Journal of Clinical Psychiatry

Volumn 59, Issue 7, 1998, Pages 352-357

  Costa e Silva, Jorge ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAPHORESIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; XEROSTOMIA;

EID: 0000488213     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v59n0703     Document Type: Article

References (26)

1. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276:293-299
2. Escobar JI, Gomez J, Tuason VB. Depressive phenomenology in North and South American patients. Am J Psychiatry 1983;140:47-51
3. Escobar JI, Tuason VB. Antidepressant agents: a cross-cultural study. Psychopharmacol Bull 1980;16:49-52
4. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249
5. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of the selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994;151:1735-1739
6. Harvey AT, Preskorn SH. Mechanism of action of venlafaxine in normal male volunteers. Presented at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics; March 5-8, 1997; San Diego, Calif
7. Tylee A, Beaumont G, Bowden M, et al. A double-blind, randomised, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Primary Care Psychiatry 1997;3:51-58
8. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:138-143
9. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:57-71
10. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976;23:56-62
13. Derogatis LR, Lipman RS, Rickels K, et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974;19:1-15
14. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994;14:99-106
15. Entsuah R, Upton GV, Rudolph R. Efficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: a meta-analysis. Hum Psychopharmacol 1995;10:195-200
16. Lecrubier Y, Bourin M, Moon CAL, et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997;95: 485-493
17. Mahapatra S, Hacked D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213
18. Schweizer E, Feighner J, Mandos LA, et al. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994;55:104-108
19. Amsterdam JD, Homig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry 1994;55:394-400
20. Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997;58(suppl 8):11-16
21. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(suppl 2):15-20
22. Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-79
23. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berl) 1986;90:131-138
24. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
25. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;16(suppl 2):37S-53S
26. Preskorn SH, Lane RM. Sertraline 50 mg: optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995;10:129-141